These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36126539)

  • 1. Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?
    Arsenault S; Benoit RY; Clift F; Moore CS
    Mult Scler Relat Disord; 2022 Nov; 67():104164. PubMed ID: 36126539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J; Wiendl H
    Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
    Geladaris A; Torke S; Weber MS
    CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
    N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
    Vermersch P; Benrabah R; Schmidt N; Zéphir H; Clavelou P; Vongsouthi C; Dubreuil P; Moussy A; Hermine O
    BMC Neurol; 2012 Jun; 12():36. PubMed ID: 22691628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
    Turner TJ; Brun P; Gruber RC; Ofengeim D
    Drugs R D; 2024 Jun; 24(2):263-274. PubMed ID: 38965189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review.
    Dybowski S; Torke S; Weber MS
    JAMA Neurol; 2023 Apr; 80(4):404-414. PubMed ID: 36780171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton tyrosine kinase inhibitors for multiple sclerosis.
    Krämer J; Bar-Or A; Turner TJ; Wiendl H
    Nat Rev Neurol; 2023 May; 19(5):289-304. PubMed ID: 37055617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
    Torke S; Weber MS
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib.
    De Bondt M; Renders J; de Prado PP; Berghmans N; Pörtner N; Vanbrabant L; de Oliveira VLS; Duran G; Baeten P; Broux B; Gouwy M; Matthys P; Hellings N; Struyf S
    J Leukoc Biol; 2024 Jul; ():. PubMed ID: 38976501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
    Greenberg BM
    Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
    von Hundelshausen P; Siess W
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.